ritobegron
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2003 (NCT02259907)
Timeline
Indications
Mechanism of action
- Beta-3 adrenergic receptorAGONIST
ADRB3 agonist
Not in current pipeline
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(OCC(=O)O)c(C)cc1CCN[C@@H](C)[C@H](O)c1ccc(O)cc1- Mol. weight
- 373.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107773 ↗
Also known as
- 2-(4-(2-((2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)-2,5-dimethylphenyloxy)acetic acid
- ethyl 2-(4-(2-((2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)-2,5-dimethylphenyloxy)acetate
- kuc-7322
- kuc-7483
- kuc-7483
- kuc-7483
- kuc-7483
- ritobegron
- ritobegron
- ritobegron
- ritobegron
- ritobegron ethyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01004315 | Phase 3 | Oct 27, 2009 | Kissei Pharmaceuticals |
| NCT01003405 | Phase 3 | Oct 27, 2009 | Kissei Pharmaceuticals |
| NCT00742833 | Phase 2 | Aug 5, 2008 | Kissei Pharmaceuticals |
| NCT02256722 | Phase 1 | Oct 1, 2005 | Boehringer Ingelheim |
| NCT02259764 | Phase 1 | Aug 1, 2004 | Boehringer Ingelheim |
| NCT02259933 | Phase 1 | Feb 1, 2004 | Boehringer Ingelheim |
| NCT02259751 | Phase 1 | Feb 1, 2004 | Boehringer Ingelheim |
| NCT02259920 | Phase 1 | Dec 1, 2003 | Boehringer Ingelheim |
| NCT02259907 | Phase 1 | May 1, 2003 | Boehringer Ingelheim |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 6 | 6 | 1 | 2003 |
| Kissei Pharmaceuticals | For profit | 3 | 3 | 2 | 2008 |
2 organizations
Page 1 / 1